Inactive Instrument

AgeX Therapeutics, Inc. Share Price

AGE

US00848H2076

Latest news : AgeX Therapeutics, Inc.

26/24/26	Serina Therapeutics, Inc. completed the acquisition of AgeX Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	CI
23/24/23	AgeX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
12/24/12	AgeX Therapeutics, Inc. Appoints Steven Mintz as a Director, Member of Audit Committee, Compensation Committee and Nominating & Corporate Governance Committee	CI
17/23/17	Pfizer Signs License Agreement With Serina Therapeutics to Gain Access to POZ Polymer Technology	MT
15/23/15	Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q3 Revenue $67,000	MT
15/23/15	AgeX Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
09/23/09	AgeX Therapeutics, Inc. Announces Departure of Dr. Michael H. May as Director of the Company	CI
30/23/30	Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. from shareholders in a reverse merger transaction.	CI
15/23/15	Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q2 Revenue $9,000	MT
15/23/15	AgeX Therapeutics, Inc. Announces CEO Changes	CI
15/23/15	Agex Therapeutics, Inc. Appoints Jean-Christophe Renondin on the Board of Directors, and Member of Audit Committee, Compensation Committee, and as Chair of the Nominating and Corporate Governance Committee	CI
15/23/15	AgeX Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
25/23/25	AgeX Therapeutics Issues Preferred Shares to Juvenescence in Exchange for Debt Cancellation	MT

More news

Press Releases: AgeX Therapeutics, Inc.

23/24/23	AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results	AQ
28/24/28	AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE	BU
29/23/29	AgeX Therapeutics : New Financial Obligation - Form 8-K	PU
02/23/02	AgeX Therapeutics : Termination of Material Agreement - Form 8-K	PU
15/23/15	AgeX Therapeutics Reports Third Quarter 2023 Financial Results	BU

More press releases

News in other languages: AgeX Therapeutics, Inc.

30/23/30	USA-Les valeurs à suivre à Wall Street (actualisé)
16/21/16	MÄRKTE USA/Uneinheitlich - Dow und S&P-500 mit neuen Rekordhochs
16/21/16	MÄRKTE USA/Schwache Daten aus China und USA animieren zu Gewinnmitnahmen
16/21/16	MÄRKTE USA/Schwache Daten aus China und USA drücken
16/21/16	MÄRKTE USA/Wall Street mit schwachen China-Daten leichter erwartet

More news

AgeX Therapeutics Inc. is a biotechnology company. The Company is focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. The Company's proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows utilizing telomerase-expressing regenerative pluripotent stem cells (PSCs) for the manufacture of cell-based therapies. Its cell-based therapeutic candidates in development are AGEX-BAT1 and AGEX-VASC1. AGEX-BAT1 is a cell therapy product candidate in the discovery stage of development utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders such as Type II (adult-onset) diabetes and obesity. AGEX-VASC1 is a cell-based therapy comprised of young regenerative vascular-forming cells. AGEX-VASC1 may restore vascular support in aged ischemic tissues such as in peripheral vascular disease and ischemic heart disease.

Employees

Sector

More about the company